Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

New Antiepileptic Drugs: Comparison of Key Clinical Trials

Cramer, Joyce A., Fisher, Robert, Ben‐Menachem, Elinor, French, Jacqueline, Mattson, Richard H.·1999·Epilepsia

Abstract

Summary: Purpose: Data accrued from clinical trials of five new antiepileptic drugs (AEDs) are compared for efficacy in reducing seizures and self‐reported adverse events as a basis of selection among new AEDs. Drawbacks to use of these data also are demonstrated. Methods: A review of double‐blind, placebo‐controlled clinical trials of a new AED or placebo added to a standard AED provided data on reduction of complex partial seizures (CPSs). Success is 50% fewer CPSs with a new AED or placebo; Overall Improvement is the success rate with drug minus the success rate with placebo. Adverse events were tabulated from product‐labeling lists of COSTART items (incidence, 5%). The Summary Complaint score is the total number of reports of individual events for each AED. Results: Efficacy data demonstrate differences in Overall Improvement rates among five new AEDs and placebos (p =0.001). However, rates of response to placebo also differed significantly among trials (p = 0.01). Adverse events predominantly affect central nervous system, psychiatric, and general body systems. However, patients in the placebo control groups did not consistently report adverse effects. Summary Complaint scores differ among the five new AEDs, but variability in use of COSTART terms nullifies comparisons. Conclusions: Comparisons of data for five new AEDs provide information for selection among treatments when a second drug is needed to improve control of CPSs. However, significant differences among the control groups and other problems make comparisons between trials problematic. The final choice should be based on the need of the individual patient for superior seizure control versus minimal adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1157.1999.tb05561.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Metadata

Authors
Cramer, J. A., Fisher, R., Ben‐Menachem, E., French, J., & Mattson, R. H.
Venue
Epilepsia
Publisher
Wiley
Published
1999-05
Volume
40
Issue
5
Pages
590-600
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2073587246
Cited by
187
References
1
FWCI
8.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Antiepileptic Drugs: Comparison of Key Clinical Trials. https://app.cochat.ai/papers/10.1111/j.1528-1157.1999.tb05561.x
The paper
Cramer, J. A., Fisher, R., Ben‐Menachem, E., French, J., & Mattson, R. H. (1999). New Antiepileptic Drugs: Comparison of Key Clinical Trials. Epilepsia. https://doi.org/10.1111/j.1528-1157.1999.tb05561.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.